About Lexeo Therapeutics, Inc. Common Stock
https://www.lexeotx.comLexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.
CEO
R. Nolan Townsend
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 89
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Leerink Partners
Outperform
RBC Capital
Outperform
JP Morgan
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:6.11M
Value:$47.13M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:4.42M
Value:$34.16M
BALYASNY ASSET MANAGEMENT L.P.
Shares:3.91M
Value:$30.21M
Summary
Showing Top 3 of 116
About Lexeo Therapeutics, Inc. Common Stock
https://www.lexeotx.comLexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $21.12M ▼ | $-20.28M ▲ | 0% | $-0.33 ▲ | $-19.73M ▲ |
| Q2-2025 | $0 | $30.18M ▼ | $-26.1M ▲ | 0% | $-0.6 ▲ | $-25.53M ▲ |
| Q1-2025 | $0 | $33.8M ▲ | $-32.66M ▼ | 0% | $-0.99 ▼ | $-32.12M ▼ |
| Q4-2024 | $0 | $27.38M ▼ | $-25.92M ▲ | 0% | $-0.78 ▲ | $-25.37M ▲ |
| Q3-2024 | $0 | $31.54M | $-29.49M | 0% | $-0.89 | $-28.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $41M ▼ | $143.84M ▼ | $23.01M ▼ | $120.83M ▼ |
| Q2-2025 | $132.89M ▲ | $176.07M ▲ | $37.85M ▲ | $138.22M ▲ |
| Q1-2025 | $99.83M ▼ | $125.69M ▼ | $37.58M ▲ | $88.11M ▼ |
| Q4-2024 | $121.52M ▼ | $146.94M ▼ | $30.1M ▼ | $116.84M ▼ |
| Q3-2024 | $157.02M | $173.87M | $34.54M | $139.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.28M ▲ | $-29.55M ▼ | $35.01M ▲ | $52K ▼ | $5.52M ▼ | $-29.84M ▼ |
| Q2-2025 | $-26.1M ▲ | $-27.22M ▼ | $-39.17M ▼ | $72.96M ▲ | $6.57M ▲ | $-27.33M ▼ |
| Q1-2025 | $-32.66M ▼ | $-21.72M ▲ | $15.6M ▲ | $11K ▲ | $-6.11M ▲ | $-21.72M ▲ |
| Q4-2024 | $-25.92M ▲ | $-28.33M ▼ | $-93.58M ▼ | $-97K ▼ | $-122.01M ▼ | $-28.31M ▼ |
| Q3-2024 | $-29.49M | $-17.81M | $-83K | $-72K | $-17.96M | $-17.89M |
CEO
R. Nolan Townsend
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 89
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Leerink Partners
Outperform
RBC Capital
Outperform
JP Morgan
Overweight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:6.11M
Value:$47.13M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:4.42M
Value:$34.16M
BALYASNY ASSET MANAGEMENT L.P.
Shares:3.91M
Value:$30.21M
Summary
Showing Top 3 of 116